Notice for tucatinib (AA-Med Pty Ltd)
Active ingredients
tucatinib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant, or metastatic setting.